ProPhase Labs, Inc. (NASDAQ:PRPH – Free Report) – Stock analysts at Diamond Equity decreased their Q4 2024 earnings per share (EPS) estimates for shares of ProPhase Labs in a note issued to investors on Monday, November 13th. Diamond Equity analyst H. Diamond now anticipates that the company will post earnings per share of $0.03 for the quarter, down from their prior estimate of $0.04. The consensus estimate for ProPhase Labs’ current full-year earnings is ($0.52) per share.
A number of other brokerages also recently weighed in on PRPH. HC Wainwright lowered their target price on ProPhase Labs from $14.00 to $11.00 and set a “buy” rating for the company in a report on Friday, November 10th. TheStreet downgraded shares of ProPhase Labs from a “c-” rating to a “d+” rating in a research report on Monday, October 16th. Finally, StockNews.com cut shares of ProPhase Labs from a “hold” rating to a “sell” rating in a report on Thursday, October 19th.
ProPhase Labs Price Performance
Shares of NASDAQ:PRPH opened at $4.35 on Thursday. ProPhase Labs has a 1 year low of $4.05 and a 1 year high of $12.30. The company has a debt-to-equity ratio of 0.18, a current ratio of 4.02 and a quick ratio of 3.75. The business’s 50-day moving average is $4.48 and its 200-day moving average is $6.28. The company has a market capitalization of $73.25 million, a price-to-earnings ratio of -7.91 and a beta of -0.33.
Institutional Investors Weigh In On ProPhase Labs
A number of hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in ProPhase Labs by 2.9% in the 1st quarter. Vanguard Group Inc. now owns 512,609 shares of the company’s stock valued at $3,588,000 after acquiring an additional 14,671 shares in the last quarter. State Street Corp grew its holdings in ProPhase Labs by 14.2% during the first quarter. State Street Corp now owns 31,063 shares of the company’s stock worth $217,000 after buying an additional 3,868 shares in the last quarter. Renaissance Technologies LLC raised its position in ProPhase Labs by 12.6% in the 2nd quarter. Renaissance Technologies LLC now owns 250,610 shares of the company’s stock valued at $3,178,000 after buying an additional 28,000 shares during the last quarter. Millennium Management LLC bought a new position in ProPhase Labs during the 2nd quarter valued at $324,000. Finally, Cubist Systematic Strategies LLC bought a new position in shares of ProPhase Labs during the second quarter valued at about $194,000. Institutional investors and hedge funds own 34.19% of the company’s stock.
ProPhase Labs Company Profile
ProPhase Labs, Inc engages in the development and commercialization of novel drugs, dietary supplements, and compounds in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It provides a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.
- Five stocks we like better than ProPhase Labs
- 3 Small Caps With Big Return Potential
- New Disney investor propels stock to ranks of best S&P gainers
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Buffett’s latest portfolio additions, trims, and cuts in Q3
- What is the S&P 500 and How It is Distinct from Other Indexes
- 5 reasons TJX Companies will hit new highs in 2024
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.